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Introduction
Current treatment for human immunodeficiency virus (HIV) infection employs combination antiretroviral 
therapy (cART), which effectively suppresses HIV replication, reduces viremia to levels below the limit of  
detection of  clinical assays, and substantially reduces morbidity and mortality of  HIV-infected patients 
(1). However, cART does not eradicate HIV and consequently lifelong ART is required. One important 
mechanism that allows HIV to persist in HIV+ individuals in spite of  treatment with highly potent cART 
is the existence and maintenance of  a stable population of  long-lived latently infected cells, i.e., the HIV 
latent reservoir (2, 3). Recently, extensive efforts have focused on developing novel therapeutics to purge the 
reservoir, and ultimately cure HIV infection (4–8). One promising strategy involves treating patients with 
a class of  drugs, termed latency-reversing agents (LRAs), which induce HIV gene expression in latently 
infected cells. Although cells that express virus or antigen might then die due to viral cytopathic effects, 
current strategies now seek to employ immune-mediated clearance mechanisms to eliminate infected cells.
A range of  LRAs have been proposed recently (9). They include histone deacetylase inhibitors (HDACis) 
such as vorinostat (10–13), romidepsin (14), and panobinostat (15), histone methyltransferases inhibitors 
(16), the anti-alcoholism drug disulfiram (17, 18), protein kinase C agonists such as bryostatin-1 (19), and 
bromodomain inhibitors such as JQ1 (20). Several LRAs have already been tested in clinical trials, and 
trials for other LRAs with a variety of  drugs/therapeutic vaccines are underway (6, 7, 9). The availability 
of  a large number of  LRA candidates raises important questions about how to evaluate and compare 
candidate LRAs prior to in vivo testing, rationally select promising LRA dosing strategies or LRA combi-
nations for in vivo testing, and determine which characteristics of  LRA performance must be improved. 
HIV eradication studies have focused on developing latency-reversing agents (LRAs). However, 
it is not understood how the rate of latent reservoir reduction is affected by different steps in the 
process of latency reversal. Furthermore, as current LRAs are host-directed, LRA treatment is likely 
to be intermittent to avoid host toxicities. Few careful studies of the serial effects of pulsatile LRA 
treatment have yet been done. This lack of clarity makes it difficult to evaluate the efficacy of 
candidate LRAs or predict long-term treatment outcomes. We constructed a mathematical model 
that describes the dynamics of latently infected cells under LRA treatment. Model analysis showed 
that, in addition to increasing the immune recognition and clearance of infected cells, the duration 
of HIV antigen expression (i.e., the period of vulnerability) plays an important role in determining 
the efficacy of LRAs, especially if effective clearance is achieved. Patients may benefit from 
pulsatile LRA exposures compared with continuous LRA exposures if the period of vulnerability is 
long and the clearance rate is high, both in the presence and absence of an LRA. Overall, the model 
framework serves as a useful tool to evaluate the efficacy and the rational design of LRAs and 
combination strategies.
Currently, studies have focused on the impact of  LRAs on latency reversal or clearance processes (10–13, 
15, 18, 21, 22). Assessment of  this is primarily based on experimental determination of  the extent of  
increase in markers of  HIV gene expression, such as cell-associated unspliced (CA-US) HIV RNA (10, 12, 
13, 21) and intracellular HIV proteins (23). Other methods to assess LRA effectiveness include measuring 
the number of  cells with integrated HIV DNA or the size of  the replication-competent reservoir using viral 
outgrowth assays (24–28). However, latency reversal is a dynamic process potentially affected by many 
processes, including activation of  HIV gene expression and subsequent expression of  HIV antigen, clear-
ance of  induced cells, reestablishment of  latency after HIV expression (22), and cell proliferation (28–30). 
Therefore, a quantitative framework that might integrate these processes is needed to formally evaluate the 
efficacy of  candidate LRAs and improve the design of  further studies (31, 32).
Mathematical modeling has been used to understand the dynamics of  the HIV latent reservoir under 
cART and LRAs (31–35) as well as HIV rebound that results from activation of  latently infected cells after 
cessation of  ART (36). In particular, one recent modeling study on LRAs pointed out that the impact of  
two LRAs may be different even when experimental measurements of  HIV expression yield similar read-
outs (32). Here, we develop a mathematical model specifically focusing on each step of  latency reversal 
under LRA therapy and how the rate of  processes in each step determines LRA efficacy. It is likely that a 
pulsatile LRA exposure is needed to minimize the side effects of  an LRA, as in previous clinical trials for 
panobinostat (15) and vorinostat (11). We thus derive general principles of  how LRA efficacy may depend 
on the dynamics of  latency reversal and LRA exposure patterns.
Results
Definition of  LRA efficacy. First, a measure for LRA efficacy is needed. Previously, mathematical mod-
els have provided the framework to estimate the efficacy of  cART (37–40). cART inhibits or disrupts 
steps in the HIV viral life cycle and therefore efficacy is estimated in terms of  the drug-induced reduc-
tion in the rate of  the targeted life-cycle step. For example, the efficacy of  a protease inhibitor can be 
defined by the reduction in the rate of  infectious virion production (41), whereas the efficacy of  an 
integrase inhibitor can be defined by the reduction in the rate of  proviral integration (42). However, 
LRAs act by inducing HIV gene expression in latently infected cells such that those cells can be recog-
nized and killed/cleared by viral cytopathic effects or host immune responses. Thus, the definition of  
efficacy for cART does not apply to LRAs. Given that the overall goal of  LRAs is to reduce the size 
of  the HIV latent reservoir, here we measure the efficacy of  LRAs as the reduction of  the size of  the 
reservoir after a certain period of  time (e.g., treatment and follow-up periods used in clinical trials) and 
use this definition to evaluate the impact of  LRAs.
A model for latency reversal with an LRA. To understand the latency-reversing process under LRAs, we 
first developed a model using ordinary differential equations (ODEs; see Methods) based on previous mod-
els (31, 33, 43). The model incorporates several key steps in the latency reversal process under an LRA 
(Figure 1). First, we consider the induction of  HIV gene expression and subsequent HIV antigen expres-
sion. The rate of  this step is described by parameter α, the latency reversal (LR) rate in the model. Second, 
we consider recognition and clearance of  these now vulnerable infected cells by the immune system or 
viral cytopathic effects (although current LRAs seem to be insufficient to induce a high level of  viral pro-
duction). The rate of  this step is described by the parameter δ, the clearance rate in the model. Third, we 
consider an LRA refractory period before latency reestablishment. Induced cells can reestablish latency 
because activation of  HIV expression by an LRA is not permanent. If  induced cells are not cleared, over 
time viral and cellular factors may become insufficient to support HIV expression, leading to reestablish-
ment of  latency (22, 31). In addition, studies using the LRA vorinostat showed that a population of  cells 
exposed to this LRA go through a period during which they become relatively unresponsive to a subsequent 
exposure to vorinostat (10, 11). This may be due to downregulation of  positive regulators of  transcription, 
such as histone acetyl transferases, and/or transcriptional repression through upregulation of  trimethyla-
tion at transcription start sites (44, 45). Here, without losing generality, we include this refractory period in 
the model, although this period can be set to 0 for LRAs that do not induce a refractory period. The rates 
of  the transition of  cells from an induced state to a refractory state and then to latency reestablishment are 
described by the parameter γ (the exit rate), and the parameter ω (the latency re-establishment rate) in the 
model, respectively. Note that 1/γ is the period of  vulnerability (for immune killing) and 1/ω is the refrac-
tory period of  latently infected cells.
Determinants of  LRA efficacy — analytical approximation. In order to understand how the LRA efficacy 
depends on the key parameter values in our model, we first derived analytical approximations to the long-
term dynamics of  the latent reservoir in the presence of  LRAs (see supplemental text; supplemental materi-
al available online with this article; https://doi.org/10.1172/jci.insight.123052DS1). The model (equation 
II in Methods) predicts that the total size of  the reservoir decreases exponentially in the long term. To 
intuitively understand the overall effect of  an LRA, we further make the simplifying assumption that the 
induced cells (A) go to the uninduced state (L) directly without going through the refractory state. The 
exponential decrease rate (Ψ) that can then be approximated as shown in equation I:
   (I)
The value of  Ψ then serves as a measure of  LRA efficacy under LRA exposure. A few simple rules can 
be derived from the expression for Ψ: (a) α and δ always appears together as sums or products. This suggests 
that the LR rate α and the clearance rate δ are equally important in determining LRA efficacy. (b) When the 
deactivation rate γ is very small compared with α + δ, γ can be neglected in the α + γ + δ term, i.e., α + γ + δ 
≈ α + δ. Then, the following simple expressions for Ψ can be derived: Ψ ≈ α – ρ, when α < δ, and Ψ ≈ δ – ρ, 
when α > δ. This suggests that the efficacy of  an LRA is mostly driven by the slower of  the 2 rates α and δ 
when the deactivation rate γ is small.
When the sum of  α and δ (i.e., α + δ) is kept a constant (e.g., in cases where there exists a trade-off  
between optimizing the LR rate and the clearance rate), maximizing the product of  α and δ always 
maximizes Ψ.
The strong dependence of  Ψ on the proliferation rate ρ suggests that changes in this rate during LRA 
interventions would have major impact on the efficacy of  the interventions.
Determinants of  LRA efficacy — simulation of  clinical trials. We then performed model simulations to 
assess the impact of  LRA therapy on the size of  reservoir reduction under a clinical setting where an 
LRA is administered in cycles (11). We first performed simulations for one LRA dosing cycle, where we 
assume a patient is on an LRA for 1 day and off  an LRA for 2 days (as in previous clinical trials; see 
ref. 11). In our previous work, we estimated that for vorinostat, the LR rate is in general high (1.8/day 
on average); however, the induced cell clearance rate is very low (<0.1/day) (31). With these parameter 
values, the reservoir reduction is small, approximately 5% (Figure 2A). If  the induced cell clearance rate 
Figure 1. Diagram of a compartmental model for the dynamics of the HIV latent reservoir on and after latency reversing agent (LRA) exposure. 
In the absence of an LRA, the unactivated (resting) latently infected cell population (L and blue dots) is affected by cell proliferation, natural cell 
death, and natural cell activation (at per capita rates, ρ, d, and η, respectively). Upon LRA exposure, latently infected cells become induced (A and 
red dots) at per capita rate α (i.e., the latency reversal [LR] rate). Over time, the induced cells either are killed/cleared by immune effector cells at per 
capita rate δ (i.e., the clearance rate) or lose induction and become refractory to further immediate latency reversal (R and green dots) at per capita 
rate γ (the exit rate). Cells in a refractory state return to the latent but responsive state (L) at rate ω. After LRA exposure, if induced cells stay in the 
induced state, e.g., HIV antigen is continuously expressed on the cell surface, induced cells can still be cleared by immune effector cells; otherwise, 
they become refractory to LRA and eventually return to an unactivated state. A second cycle of LRA treatment may then proceed, leading to further 
reduction in the reservoir size. All latently infected cells proliferate at per capita rate ρ.
increases from 0.05 to 0.5 per day, then the reservoir reduction changes from 5% to 40% for one dos-
ing cycle of  LRA treatment. This is not surprising because in order to reduce the size of  the reservoir, 
latently infected cells have to be induced and then cleared.
We then considered treatments with multiple dosing cycles. In a clinical trial reported by Archin et 
al. (11), a patient is given multiple dosing cycles of  the LRA vorinostat with approximately 72 hours 
between each dose (dosing every 3 days). Here, we use our model to evaluate the impact of  pulsatile 
treatment regimens on the latent reservoir. We assume that in a pulsatile treatment, a patient is treated 
for a total of  10 doses, with the LRA given every third day, as in the protocol selected by Archin et al. 
(11). Further, we assume that after a dose is given the LRA is active for 1 day and then inactive for the 
next 2 days. More realistic models could incorporate drug-specific pharmacokinetics and pharmacody-
namics. The size of  the reservoir is measured during a follow-up at 4 weeks after the last LRA dose as 
a measure of  LRA efficacy. As seen in the 1-dosing-cycle simulations (Figure 2A), we found that with 
pulsatile treatment increasing the clearance rate induced by the LRA would also substantially increase 
the LRA efficacy. As shown in Figure 2B, the reservoir size was reduced by 99.2% when δ = 0.5/day 
after 10 dosing cycles compared with 42% when δ = 0.05/day.
We further explored how the reduction in the reservoir size depends on variations of  the parameters 
in the model. We found that increasing both the LR rate and the clearance rate would greatly improve 
Figure 2. The dynamics of the HIV latent reservoir under single or multiple LRA dosing cycles and the depen-
dence of the LRA efficacy on the induced cell clearance rate. (A) Time course simulations of the mathematical 
model showing the reservoir dynamics during one LRA dosing cycle, where a patient is treated with LRA for 1 day 
(shaded in light red) followed by a 2-day resting period. The only difference between the 2 simulations is that δ = 
0.05/day in the simulation on the left and δ = 0.5/day in the simulation on the right. The uninduced cells (L), the 
induced cells (A), the refractory cells (R), and the size of latent reservoir (L + A + R) are shown in blue, red, green, 
and black, respectively. (B) Time course simulations of the reservoir dynamics during and after 10 LRA dosing 
cycles. In both panel A and B, increasing the clearance rate from 0.05/day to 0.5/day significantly increases the 
LRA efficacy. Baseline parameter values used are α = 1.8/day on LRA, α = 0/day off LRA, γ = 0.5/day, ω = 1/day,  
ρ = 0.0072/day, d = 0.006/day, η = 0.0017/day (unless varied as indicated on the plots).
LRA efficacy (Figure 3A). Unsurprisingly, the LR rate, α, and the clearance rate, δ, are equally important 
for reservoir reduction, and the highest reduction is achieved when both rates are high, a result consistent 
with our analytical approximation. With the previously estimated LR and clearance rates (α = 1.8/day 
and δ < 0.1/day; ‘×’ in Figure 3A), a priority would be increasing the clearance rate. For example, if  the 
clearance rate is increased to 0.2, 0.5, or 0.8/day, there will be approximately a 10-, 100-, or 1,000-fold 
reduction, respectively, in the reservoir size after 10 LRA doses.
We then examined the impact of  changes in the exit rate (γ) and the latency re-establishment rate (ω) on 
LRA efficacy (Figure 3B). Note again that 1/γ is the period of  vulnerability (for immune killing) and 1/ω 
is the refractory period of  latently infected cells. With the previously estimated LR and clearance rates (α = 
1.8/day and δ < 0.1/day; ‘×’ in Figure 3B), increasing the period of  vulnerability or decreasing the refracto-
ry period will not substantially improve the LRA’s efficacy (Figure 3, B and C). However, with an effective 
LRA (or combinations of  LRAs) such that the clearance rate is increased (e.g., to 0.5/day), increasing the 
period of  vulnerability will achieve substantial reservoir reduction (Figure 3B). Decreasing the refractory 
period can further deplete the reservoir, although its impact is not as strong as increasing the LR rate, the 
clearance rate, or the period of  vulnerability (Figure 3C).
The model predictions above suggest that an obvious priority for developing LRAs or combination 
therapies currently is focusing on improving HIV antigen expression to increase the ability of  the immune 
response to recognize and clear induced cells. Once an LRA that effectively reduces the size of  reservoir is 
identified, efforts that aim to increase the period of  vulnerability can be very useful.
LRA properties that improve efficacy in a pulsatile LRA regimen. As LRAs are directed at host rather than viral 
targets, side effects and toxicities are likely (12, 46). Thus, to achieve a clinically relevant reservoir reduction, 
multiple LRA exposures where a resting period in between LRA dosing is necessary to avoid side effects, 
i.e., a pulsatile LRA regimen should be used. We used our model to identify the characteristics of  an LRA
that can improve efficacy in a pulsatile LRA regimen compared with a continuous LRA regimen (Figure 4).
We simulated the model under a 10-dose-cycle pulsatile regimen and compared the results with a continuous 
10-day dosing regimen (Figure 4, A and B). Results show surprisingly that when the clearance rate δ is high
and the period of  vulnerability is long both on and off  the LRA, a pulsatile treatment regimen may reduce
the latent reservoir to a lower level than a continuous treatment regimen (Figure 4D). A pulsatile regimen
is beneficial because once latently infected cells are induced by an LRA, these cells may remain vulnerable
for a long period of  time and thus may be effectively cleared despite the rest period in between LRA doses
(Figure 4B). We further simulated the model to explore how the reduction in the reservoir size changes with
variations in the pulsatile dosing pattern. In general, we found that one LRA dose followed by a sufficiently
long resting period before another LRA dose is the best strategy (Supplemental Figure 1), although this
result must be taken cautiously because many factors that are not considered in our model may also be
important in determining the best treatment strategy, some of  which are outlined below.
Essential to the prediction of  the benefit of  a pulsatile treatment is the assumption that the period of  
vulnerability continues for some time after LRA dosing. This assumption implies that once an HIV antigen 
Figure 3. The determinants of LRA efficacy in a 10-dose LRA cycle regimen. (A) The LR rate (α) and the clearance rate (δ) are equally important in deter-
mining LRA efficacy. Color indicates reservoir reduction (r.r.) (in log10) at 4-week follow-up after a 10-dose LRA cycle regimen. (B) Increasing the period of 
vulnerability (1/γ) can substantially increase LRA efficacy when the clearance rate, δ, is high. (C) Decreasing the refractory period (1/ω) can further reduce 
the reservoir size when the clearance rate, δ, is high, although the impact of this parameter on reservoir reduction is not as strong as that of α, δ, γ, and ω. 
Across the 3 panels, ‘×’ shows the baseline parameter values used (given in the caption for Figure 2).
is expressed on a cell surface, the duration of  the antigen expression is long irrespective of  the presence of  
LRA, leading to a long period of  vulnerability. This is plausible if  after LRA induction, either the duration 
of  HIV gene expression is mostly determined by properties of  the HIV gene regulatory circuit (47) or the 
LRA induces long-lasting changes in the cell state such that sustained HIV gene expression is possible 
(13, 31). Whether this occurs or not is complex, as HIV expression is dependent on many cellular factors, 
including histone acetylation status (48–51), positive regulators, such as p-TEFb (42–44) and NF-κB (52), 
as well as inhibitory molecules, such as Murr1 and human schlafen 11 (45, 46).
Removal of an LRA can lead to changes in expression of host factors (14, 15). This may or may not lead to 
repression of HIV expression (22), depending on the LRA. If HIV expression is dampened and antigen disap-
pears from the cell surface quickly in the absence of LRA, the cells would quickly become invisible to immune 
effector cells. In this case, the exit rate would be different during LRA and after LRA (which are denoted in the 
model as γon and γoff, respectively), and the period of vulnerability would be shortened, i.e., γoff > γon. Our model
results show that a pulsatile treatment regimen may be less effective in reducing the reservoir size compared with 
a continuous treatment especially when γoff > γon and the clearance rate, δ, is high (dark blue region in Figure 4E). 
In this case, during the holiday periods induced cells mostly reestablish latency (rather than being killed).
Overall, our results suggest that an LRA that induces a long period of  vulnerability of  latently infected 
cells both during and after LRA treatment would be more effective in reducing the reservoir size with a 
pulsatile regimen than with a continuous regimen.
The role of  latently infected cell proliferation. Recent work suggests that homeostatic proliferation is an import-
ant mechanism that maintains the stability of  the latent reservoir (29, 30, 53). This implies that the stability 
Figure 4. A patient would benefit from a pulsatile regimen if an LRA induces a long period of vulnerability both on and off LRA treatment. (A) Model 
simulation for a continuous 10-day LRA exposure followed by a rest period. The period of vulnerability is assumed to be 2 days both on and off LRA (γon = γoff 
= 0.5/day). (B) A model simulation for a pulsatile LRA exposure (10 dosing cycles with 1 day on LRA and 2 days off LRA). Same as in panel A, γon = γoff = 0.5/
day. (C) Same pulsatile LRA exposure as in panel B, except that the period of vulnerability is much shorter, i.e., γoff = 10/day and1/γoff = 0.1 day. (D) Compari-
son of reservoir reduction (r.r.) between a pulsatile exposure and a continuous exposure evaluated 4 weeks after the last dose when γon = γoff. Color denotes 
the log10 ratio of the reservoir reduction in a 10-cycle pulsatile LRA exposure over the reduction in a 10-day continuous LRA exposure (followed by a 4-week 
resting period). (E) Same comparison as in panel D except that γoff is fixed at 10/day. The dashed contour line denotes parameter combinations where a 
pulsatile exposure and a continuous exposure achieve equal reservoir reduction. Baseline parameter values are the same as in the caption for Figure 2.
of the latent reservoir is achieved through a balance of  proliferation, activation, and death. To investigate the 
importance of  the homeostatic proliferation rate (ρ) in determining LRA efficacy, we examined how changes 
in this rate affect reservoir reduction. Interventions such as antiproliferative drugs (35, 54) have been suggest-
ed to reduce the size of  the reservoir. Thus, we first focused on the impact of  reducing the proliferation rate 
both in the presence and the absence of  an LRA (Figure 5A). A slight decrease in this rate leads to relatively 
large reduction in the reservoir size (note the small range of  variation in ρ we tested in Figure 5A). With the 
baseline rate of  proliferation assumed in our study, i.e., ρ = 0.0072/day, the absolute reservoir reduction is not 
high even when proliferation is completely inhibited; if  the actual proliferation rate is higher than the value 
we assumed, the absolute reduction can be large. Second, we increased the proliferation rate in the presence 
of  an LRA only, to consider the impact of  a potential off-target effect of  an LRA on increasing cell prolifer-
ation. Again, a slight increase in the latent cell proliferation rate during LRA treatment would compromise 
the reduction in reservoir size. If  the increase is large, it is possible for the reservoir size to increase after LRA 
treatment (Figure 5B). These results are consistent with the insight from the analytical expressions for Ψ that 
changes in the proliferation rate can have a large impact on the reservoir size. Overall, our results suggest that 
the potential off-target effects of  LRA administration should be closely examined, and LRAs that do not 
increase proliferation would be preferred. Although HDACis may not be the ideal LRA, the fact that these 
agents do not induce proliferation or cell activation was one reason they were initially selected for testing.
Discussion
Extensive research efforts have focused on developing and testing LRAs to purge the HIV latent reservoir (5, 
8). Better methods to evaluate, select, and improve candidate LRAs are needed. Here, we developed a formal 
quantitative framework integrating essential processes of latency maintenance and reversal to quantify the 
contribution of each step of latency reversal to the reservoir decline during LRA exposure. We showed that for 
current LRAs, a priority is to improve those LRAs or to develop combination strategies to increase the clear-
ance of latently infected cells. Once such an improvement is achieved, increasing the period of vulnerability, 
i.e., the period of HIV and antigen expression, would lead to more rapid reservoir depletion. Interestingly, we 
found that patients may benefit from a pulsatile treatment regimen when the period of vulnerability is long.
Clinical and experimental studies found that LRAs induced HIV expression in latently infected cells (10, 
12, 13, 21), suggesting the latency reversal rate (α) may be relatively high. However, the impact of  LRAs on 
the latent cell clearance rate is negligible in vivo, as we and others have shown (12, 13, 15, 31). Unsurpris-
ingly, increasing the clearance rate would substantially increase the LRA efficacy, as suggested in previous 
studies (12, 13, 15, 31) and consistent with the results presented here. With the current estimate of  the LR 
Figure 5. The proliferation rate is an important parameter determining reservoir size. (A) Antiproliferation therapy (left arrow) that reduces the 
proliferation rate below its baseline value (black vertical dashed line) would enhance LRA treatment and further increase the reservoir reduction (r.r.). 
The proliferation rate is set at the indicated values both during and after LRA treatment during a 10-dosing cycle as shown in Figure 2B. (B) The pro-
liferation rate is set at the indicated values during LRA treatment only, and it is set to the baseline value 0.0072/day off LRA treatment. If an LRA 
off-target effect increases the proliferation rate (right arrow), the reservoir size will be reduced to a lesser extent, and the reservoir size may even 
increase (log10 r.r. < 0) if the increase in the proliferation rate is large enough. Colors denote the log10 reservoir reduction (log10 r.r.). Across the 2 panels, 
‘×’ shows the baseline parameter values used (given in the caption for Figure 2). The dashed contour lines denote parameter combinations where no 
reduction in the size of the reservoir is achieved, i.e., log10 r.r. = 0.
rate, we predict that there will be a 10-, 100-, or 1,000-fold reservoir reduction after 10 LRA doses, if  the 
clearance rate is increased to 0.2, 0.5, or 0.8/day, respectively. The clearance rate in our model includes 
immune recognition, binding of  and subsequent killing of  induced latently infected cells. This (with previ-
ous studies; refs. 10, 12, 13, 21) highlights the need to develop LRAs or combination strategies to increase 
the efficiency of  immune recognition and killing of  latently infected cells. The clearance of  residual HIV 
infection in the context of  prolonged suppression of  viral replication is a unique challenge for the immune 
system. Rare populations of  latently infected cells, induced by LRAs to express HIV antigen in limited 
quantity and for limited time, may be widely distributed across anatomical compartments. In some cases, 
the HIV-specific immune response may have waned or been depleted by the time of  LRA administration. 
One promising strategy is the combination of  LRAs and immunotherapies, for example using checkpoint 
inhibitors (55) or bispecific antibodies such as the dual-affinity retargeting molecules (56–58). These bispe-
cific antibodies would facilitate recognition and binding between effector cells and latently infected cells 
expressing HIV antigen. Alternatively, T cell therapeutic vaccines have been suggested to boost the recogni-
tion and killing of  latently infected cells by T cells (59, 60), although one recent clinical trial failed to show 
efficacy as measured by the time to viral rebound after ART interruption (61).
Previous studies have focused on the impact of  LRAs on the induction of  HIV expression and the 
clearance of  latently infected cells (10–13, 15, 18, 21, 22). Here, we showed that in addition, a largely over-
looked parameter (see ref. 11 for exceptions), the period of  vulnerability (i.e., the inverse of  the exit rate in 
our model), which describes the duration of  the induced state and HIV antigen expression on the surface of  
latently infected cells, plays an important role in determining LRA efficacy. The benefits of  a longer period 
of  vulnerability come from 2 sources. First, cells expressing HIV antigens for a longer period would have 
a higher chance of  being recognized and cleared by immune effector cells. Second, if  the period of  vulner-
ability is long and antigen expression continues after LRA treatment is interrupted, patients may benefit 
from a pulsatile treatment, as immune recognition and killing of  latent cells may continue during the rest 
periods between LRA doses. Thus, we argue that measurement of  the duration of  HIV antigen expression 
on latently infected cells and the efficiency of  their recognition by cytotoxic T lymphocytes (62) will be 
critical for evaluation of  LRA candidates. As far as we know this parameter has not been experimentally 
measured after LRA administration and we hope this work will stimulate attempts to measure this quantity. 
If  the duration of  antigen expression correlates with the duration of  HIV gene expression, the duration 
of  antigen expression can be estimated indirectly from experiments measuring HIV expression in latently 
infected cells over time both on and off  LRA treatment (see ref. 22 for an example). Our result also suggests 
that another dimension for optimizing LRA design is to develop LRAs that induce sustained HIV antigen 
expression on latently infected cells.
Recently, multiple lines of  evidence suggest that latently infected cell proliferation is more significant 
than previously appreciated, and may represent a major mechanism in the maintenance of  the latent res-
ervoir (29, 30, 53, 63). Thus, interventions using antiproliferative drugs (35, 54) have been proposed to 
reduce the reservoir size. Our analysis showed the profound impact of  variations in the cell proliferation 
rate on the reservoir size, consistent with a previous analysis (35). For the relatively small proliferation rate 
assumed in the model, however, we find that the reduction in the reservoir size is relatively mild, and to 
achieve substantial reduction in the reservoir size within a short period of  time, an effective LRA is needed. 
However, if  the proliferation rate is much higher than that used in the study, antiproliferative agents may be 
effective in reducing the size of  the latent reservoir (30, 35). Thus, an important direction for future work is 
to estimate the rate of  latently infected cell proliferation and the extent to which proliferation contributes 
to the maintenance of  the reservoir.
The model presented here integrates many key aspects of  latency reversal under LRA treatment. 
Inevitably, the model makes many simplifying assumptions, as the biology of  latency reversal (7) is com-
plex. First, we assumed that the latently infected cell population is a homogeneous population. However, 
latently infected cells consist of  different types of  cells, such as central memory T cells, effector mem-
ory cells, and transitional memory T cells (29). These latently infected cell populations may reside in 
different tissue compartments with different dynamics in the presence of  an LRA. Further, in addition 
to the heterogeneity in cell types, it has been shown that the replication-competent proviruses in the 
latently infected cells are heterogeneous in their CTL epitopes, and these differences may lead to differ-
ent clearance rates of  infected cells (64). Therefore, model extensions with multiple strains and multiple 
compartments accounting for different types of  latently infected cells and latent viruses in different tissue 
compartments may be useful. However, the lack of  measurements of  latent infection in heterogeneous 
cell populations in different tissue compartments limits the predictability of  such complex models. The 
general conclusions of  our model can be viewed as a mean field approximation to these more complicat-
ed situations. Second, without losing generality, we have assumed that the clearance rate of  induced cells 
is independent of  the presence or absence of  LRAs. This may be a good assumption for most LRAs but 
experimental studies have revealed exceptions (65, 66). Our model can be easily adapted to the individ-
ual characteristics of  LRAs. Third, we used a step function to describe the impact of  an LRA, i.e., the 
LR parameter, α, changes from 0 to a constant value upon LRA treatment. A model incorporating the 
pharmacokinetics and pharmacodynamics of  LRAs will be useful to evaluate how drug characteristics, 
such as their EC50 and the slope of  the dose-response curve (67–69), impacts its efficacy. Last, another 
extension of  the model is to incorporate LRA side effects into the model and explicitly describe how side 
effects depend on the pharmacokinetics of  the LRA. This type of  model will be useful to make precise 
predictions about the best way to pulse a treatment regimen, although currently the lack of  data again 
prevents such model extension. Even with all simplifying assumptions made here, the simple model we 
developed sheds light on the contribution of  each of  the steps in the latency reversal and clearance strate-
gy towards the reduction of  the HIV reservoir, such that general principles for determining LRA efficacy, 
and thus optimizing LRA combinations and treatment strategies, can be made.
Overall, we highlight the importance of  developing LRAs to induce sustained HIV antigen expres-
sion to maximize the opportunity for persistently infected cells to become vulnerable to effector mecha-
nisms, and the need for augmentation of  immune effector mechanisms to clear these targets. The model 
framework we presented here serves as a useful tool to evaluate the efficacy of  and derive design princi-
ples for LRAs and combination strategies using immunotherapies (7, 56, 58) or other approaches to clear 
persistent HIV infection.
Methods
The mathematical model. In our model we keep track of  3 types of  latently infected cell populations: unin-
duced latently infected cells (L), cells induced by an LRA (A), and cells that have become refractory to LRA 
stimulation following induction (R). The ODEs describing these cell populations are:
dL/dt = (ρ – d)L – ηL – αL + ωR
dA/dt = (ρ – δ)A + αL – γA  (II)
dR/dt = (ρ – d)R + γ A – ωR
In this model (see Figure 1 for a schematic diagram), latently infected cells (L, A, and R) all proliferate at 
per capita rate ρ. In the absence of  LRA, uninduced latently infected cells (L) die at per capita rate d, and 
are naturally activated to become productively infected cells (70) (a different population from the cells 
induced by an LRA) at per capita rate η. Throughout this study, we assume that patients are treated with 
effective cART and the contribution of  viruses produced from productively infected cells and induced cells 
to further rounds of  infection and to the latent reservoir are neglected (31, 43). Therefore, in our model, 
latently infected cells are maintained by proliferation. Although one study proposed on-going viral replica-
tion in cART sanctuaries as another major mechanism for reservoir maintenance (71), other studies suggest 
that on-going viral replication is inconsistent with a wide range of  clinical observations (72–74).
LRA treatment turns uninduced cells into induced cells (A) at rate α (the LR rate), where α > 0 in the 
presence of  an LRA and α = 0 in the absence of  an LRA. Once induced, we assume that latently infect-
ed cells produce HIV RNAs and proteins and consequently express HIV antigens. HIV antigens may be 
recognized by the immune system and the cells expressing these antigens are assumed to be killed by 
immune effector cells at per capita death rate δ (the clearance rate). If  induced cells are not recognized 
by the immune system after a certain period, HIV gene expression declines, leading to reestablishment of  
latency (instead of  death) (22) and loss of  HIV antigens from the cell surface due to lack of  production 
and continuing membrane turnover (75). In our model, we assume for simplicity that the process from loss 
of  HIV gene expression to removal of  HIV antigen from the cell surface to the extent that the cell becomes 
invisible to the immune system occurs at rate γ (we term the ‘exit rate’); cells are then in the refractory 
stage (R). Therefore, the period during which the cell is visible to the immune response, i.e., the period 
of  ‘vulnerability’ termed in other studies (11, 76), can be calculated as 1/γ. Note that, in our analyses, we 
considered the case when the period of  vulnerability is different depending on whether an LRA is pres-
ent, and the period is denoted as 1/γon and 1/γoff in the presence and absence of  an LRA, respectively. We
assume that the cells leave the refractory state and revert to uninduced cells (L) at rate ω, i.e., the cells stay 
in the refractory state (R) for an average period of  1/ω.
Parameter values. We set the death rate for uninduced cells and refractory cells, d, to 0.006/day, since 
latently infected cells are mostly resting memory CD4+ T cells, which have an estimated mean lifetime 
of  approximately 164 days (77, 78). We set the natural activation rate, η, to be 0.0017/day as previous-
ly reported (43). The rate ρ is set to 0.0072/day such that in the absence of  LRA, the half-life of  latent 
reservoir is 44 months (2, 3). Note that precise quantification of  these parameter values is lacking; other 
parameter choices could also be made that would be consistent with the observed 44-month latent reservoir 
half-life. The predictions of  the model do not strongly depend on the choice of  the death rate d and the 
natural activation rate η, as long as the half-life of  the reservoir size is set to 44 months, because these rates 
are relatively low compared with the clinically relevant timeframe of  LRA exposure that we study.
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